Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
July 12, 2024 08:02 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Hallucinogenics: Leading Dispensary in Canada Celebrates 1st Anniversary
July 09, 2024 09:00 ET
|
Hallucinogenics
Ottawa, Canada, July 09, 2024 (GLOBE NEWSWIRE) -- Hallucinogenics, a premier Magic mushroom, LSD, and DMT dispensary in Canada, is excited to announce the celebration of its 1 year anniversary of...
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 26, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Sunstone Therapies to participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 20, 2024 07:00 ET
|
Sunstone Therapies
Sunstone Therapies to participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference Rockville, Maryland, June 20, 2024 – Sunstone Therapies, a leader in the delivery of...
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
May 23, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
May 22, 2024 20:11 ET
|
Novotech
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
May 22, 2024 08:30 ET
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
May 15, 2024 06:59 ET
|
atai Life Sciences
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD...